PMC:6909918 / 18485-19472 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6909918","sourcedb":"PMC","sourceid":"6909918","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6909918","text":"Comparison of safety outcomes for regorafenib, fruquintinib, and TAS-102\nDirect and indirect comparisons of adverse events (AEs), serious adverse events (SAEs), and fatal adverse events (FAEs) were compared for patients with refractory mCRC treated with fruquintinib, regorfenib, TAS-102, and placebo. Regorafenib showed significantly increased numbers of AEs of all grades when compared with placebo (OR 1.78; 95% CI, 1.16–2.73). Regorafenib also significantly increased high-grade AEs when compared with placebo (OR 3.81; 95% CI, 1.61–9.00). Fruquintinib treatment was associated with significantly increased SAEs when compared with TAS-102 (OR 2.90; 95% CI, 1.37–6.14), and when compared with placebo (OR 2.65; 95% CI, 1.28–5.48). Regorafenib treatment was associated with a significantly lower risk of SAEs comparing with fruquintinib (OR 0.42; 95% CI, 0.20–0.89). There were no significant differences in the other direct or indirect comparisons, with the results shown in Figure 9.","divisions":[{"label":"title","span":{"begin":0,"end":72}}],"tracks":[]}